Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy
暂无分享,去创建一个
G. Breithardt | D. Singer | R. Califf | G. Hankey | J. Piccini | W. Hacke | H. White | J. Halperin | K. Mahaffey | R. Becker | K. Fox | C. Nessel | S. Berkowitz | D. Wojdyla | M. Patel
[1] L. Køber,et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. , 2012, European heart journal.
[2] C. Rowley. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[3] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[4] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[5] M. Eliasziw,et al. New options in anticoagulation for atrial fibrillation. , 2011, The New England journal of medicine.
[6] I. Abidin. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation , 2011 .
[7] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[8] S. Yusuf,et al. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation , 2010, Circulation.
[9] R. Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.
[10] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[11] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[12] W. Baker,et al. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.
[13] Susan Regan,et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.
[14] D. Singer,et al. Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study , 2006, Journal of the American Geriatrics Society.
[15] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[16] Z. Ying,et al. Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .